Q2 2023

Filed Aug 18, 2023 · 10-Q · 49 days after period end · 0001493152-23-029461

Q2 2023 · 10-Q

Revenue—

Net Income

-$6.76M

N/M vs Q2 2022

EPS, diluted—

Operating Income-$6,321,904N/M

Operating Cash Flowderived-$448,563N/M

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	—	—	—	$1.40M
Net Income	-$6.76M	$16.01M	-$3.23M	$582.09K
EPS Diluted	—	$0.04	-$0.01	$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR